Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel

Pharmacogenomics

Volumn 7, Issue 6, 2006, Pages 843-852

  Le Morvan, Valérie ^a,b   Bellott, Ricardo ^a,b   Moisan, François ^a,b   Mathoulin Pélissier, Simone ^a,b   Bonnet, Jacques ^a,b   Robert, Jacques ^a,b  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Anticancer drug cytotoxicity; Gene polymorphisms; Glutathione S transferase P1; In vitro models; Xeroderma pigmentosum group D; Xeroderma pigmentosum group G

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ASPARTIC ACID; DNA; DNA TOPOISOMERASE INHIBITOR; FOLIC ACID ANTAGONIST; GLUTATHIONE TRANSFERASE; GLYCINE; GYRASE INHIBITOR; HISTIDINE; ISOLEUCINE; LYSINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TAXANE DERIVATIVE; VALINE; VINCA ALKALOID;

AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CYTOTOXICITY; DNA REPAIR; DRUG METABOLISM; DRUG SCREENING; DRUG TRANSPORT; FACTUAL DATABASE; GENE FREQUENCY; GENETIC COMPLEMENTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE ORGANIZATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IC 50; IN VITRO STUDY; INHIBITION KINETICS; KIDNEY CANCER; LEUKEMIA CELL; LUNG CANCER; MELANOMA; OVARY CANCER; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; XERODERMA PIGMENTOSUM;

XERODERMA PIGMENTOSUM;

EID: 33748993393     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.6.843     Document Type: Article

References (25)

1. Relling MV, Dervieux T: Pharmacogenetics and cancer therapy. Nat. Rev. Cancer 1, 99-108 (2001).
2. Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J: Predicting drug response and toxicity based on gene polymorphisms. Crit. Rev. Oncol. Hematol. 54, 171-196 (2005).
3. McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14, 567-572 (2000).
4. van Kuilenburg AB, Meinsma R, Zonnenberg BA et al.: Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin. Cancer Res. 9, 4363-4367 (2003).
5. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65-70 (2001).
6. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61, 8654-8658 (2001).
7. Stoehlmacher J, Park DJ, Zhang W et al.: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl Cancer Inst. 94, 936-942 (2002).
8. Monks A, Scudiero D, Skehan P et al.: Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer Inst. 83, 757-766 (1991).
9. O'Connor PM, Jackman J, Bae I et al.: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-4300 (1997).
10. Xu Z, Chen ZP, Malapetsa A et al.: DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13, 511-519 (2002).
11. Robert J, Vekris A, Pourquier P, Bonnet J: Predicting drug response based on gene expression. Crit. Rev. Oncol. Hematol. 51, 205-227 (2004).
12. Scherf U, Ross DT, Waltham M et al.: A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236-244 (2000).
13. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J: Determinants of the clinical activity of platinum compounds: the contribution of in silico research. Cancer Res. 64, 356-362 (2004).
14. Takebayashi Y, Pourquier P, Zimonjic DB et al.: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7, 961-966 (2001).
15. Ban N, Takahashi Y, Takayama T et al.: Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 56, 3577-3582 (1996).
16. Park JY, Lee SY, Jeon HS et al.: Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. Lung Cancer 36, 15-16 (2002).
17. Kumar R, Hoglund L, Zhao C, Forsti A, Snellman E, Hemminki K: Single nucleotide polymorphisms in the XPG gene: determination of role in DNA repair and breast cancer risk. Int. J. Cancer 103, 671-675 (2003).
18. Harries LW, Stubbins MJ, Forman D, Howard GCW, Wolf CR: Identification of genetic polymorphisms at the glutathione S-transferase π locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18, 641-644 (1997).
19. Spitz MR, Wu X, Wang Y et al.: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61, 1354-1357 (2001).
20. Jeon HS, Kim KM, Park SH et al.: Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer. Carcinogenesis 24, 1677-1681 (2003).
21. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA: Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19, 275-280 (1998).
22. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV: Differential catalytic efficiency of allelic variants of human glutathione S-transferase π in catalyzing the glutathione conjugation of thiotepa. Arch. Biochem, Biophys. 366, 89-94 (1999).
23. Garraway LA, Widlund HR, Rubin MA et al.: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
24. Roschke AV, Tonon G, Gehlhaus KS et al.: Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 63, 8634-8647 (2003).
25. Cheng Q, Yang W, Raimondi SC, Pui CH, Relling MV, Evans WE: Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat. Genet. 37, 878-882 (2005).